Hercules Capital (NYSE:HTGC) Stock Price Expected to Rise, Piper Sandler Analyst Says

Key Points

• Piper Sandler raised its target price on HTGC to $17 and kept a "neutral" rating (about 3.3% upside), while the consensus target is $18.13 and analysts' average rating is "Moderate Buy."
• Q1 results beat on EPS ($0.48 vs. $0.47), showed revenue up 18.4% YoY and a record $1.81 billion in new commitments, and the firm announced a loan facility with Lexicon (up to $100M), underscoring ongoing deal flow.
• Legal risk looms as multiple securities class-action filings and allegations from a short-seller report about concealed software-debt concentrations and misstated marks could create litigation expense and pressure valuations.

Hercules Capital (NYSE:HTGC - Get Free Report) had its target price boosted by investment analysts at Piper Sandler from $16.50 to $17.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a "neutral" rating on the financial services provider's stock. Piper Sandler's price objective would suggest a potential upside of 3.32% from the company's previous close.

A number of other analysts have also commented on HTGC. Citizens Jmp cut their price target on Hercules Capital from $24.00 to $22.00 and set a "market outperform" rating on the stock in a research note on Wednesday, April 22nd. Wells Fargo & Company lowered their price objective on Hercules Capital from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Friday, February 13th. Keefe, Bruyette & Woods dropped their target price on shares of Hercules Capital from $19.00 to $18.00 and set an "outperform" rating on the stock in a report on Thursday, April 16th. Weiss Ratings cut Hercules Capital from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, February 24th. Finally, UBS Group reduced their target price on Hercules Capital from $19.50 to $15.00 and set a "neutral" rating for the company in a research note on Friday, March 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Hercules Capital has an average rating of "Moderate Buy" and a consensus target price of $18.13.

Hercules Capital Price Performance

NYSE HTGC traded down $0.12 on Wednesday, hitting $16.45. 1,061,945 shares of the company's stock were exchanged, compared to its average volume of 2,431,310. The stock has a 50-day moving average of $14.94 and a 200-day moving average of $16.91. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 1.03. Hercules Capital has a 52 week low of $13.70 and a 52 week high of $19.67. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of 9.01 and a beta of 0.82.

Hercules Capital (NYSE:HTGC - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The financial services provider reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.01. Hercules Capital had a return on equity of 15.97% and a net margin of 63.80%.The company had revenue of $134.94 million for the quarter, compared to analyst estimates of $141.39 million. During the same quarter last year, the company posted $0.45 EPS. The company's revenue for the quarter was up 18.4% compared to the same quarter last year. Analysts expect that Hercules Capital will post 1.95 earnings per share for the current year.

Insider Transactions at Hercules Capital

In other Hercules Capital news, CEO Scott Bluestein bought 7,000 shares of Hercules Capital stock in a transaction dated Friday, February 27th. The stock was bought at an average cost of $14.35 per share, with a total value of $100,450.00. Following the completion of the acquisition, the chief executive officer directly owned 2,516,379 shares in the company, valued at approximately $36,110,038.65. The trade was a 0.28% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Robert P. Badavas acquired 5,000 shares of Hercules Capital stock in a transaction on Friday, February 27th. The stock was acquired at an average price of $14.27 per share, with a total value of $71,350.00. Following the purchase, the director directly owned 122,073 shares in the company, valued at approximately $1,741,981.71. This trade represents a 4.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have bought 117,015 shares of company stock worth $1,749,620. Company insiders own 1.80% of the company's stock.

Institutional Investors Weigh In On Hercules Capital

Several large investors have recently modified their holdings of HTGC. Wealth Enhancement Advisory Services LLC increased its stake in shares of Hercules Capital by 173.3% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 89,575 shares of the financial services provider's stock worth $1,605,000 after purchasing an additional 56,797 shares in the last quarter. Tectonic Advisors LLC lifted its stake in Hercules Capital by 10.2% in the 4th quarter. Tectonic Advisors LLC now owns 759,746 shares of the financial services provider's stock worth $14,298,000 after purchasing an additional 70,235 shares in the last quarter. International Assets Investment Management LLC boosted its stake in Hercules Capital by 308.9% during the third quarter. International Assets Investment Management LLC now owns 79,555 shares of the financial services provider's stock valued at $1,493,000 after buying an additional 60,100 shares during the period. Tred Avon Family Wealth LLC purchased a new position in Hercules Capital during the third quarter worth about $1,042,000. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in Hercules Capital by 42.3% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 884,946 shares of the financial services provider's stock worth $16,734,000 after buying an additional 263,222 shares in the last quarter. Hedge funds and other institutional investors own 19.69% of the company's stock.

Key Hercules Capital News

Here are the key news stories impacting Hercules Capital this week:

• Positive Sentiment: Q1 results outperformed on EPS and showed strong portfolio activity — EPS $0.48 vs. $0.47 consensus and the firm logged a record $1.81 billion in new commitments, which supports future yield and fee income. Hercules Capital Q1 Earnings Beat
• Positive Sentiment: Company announced a loan facility with Lexicon Pharmaceuticals (up to $100M), demonstrating ongoing deal activity and demand for Hercules’ financing. Lexicon Loan Facility
• Neutral Sentiment: Hercules published its full Q1 release, slide deck and call materials (revenue up 18.4% YoY but slightly below some estimates), providing detail for investors to parse credit quality and mark methodology. Hercules Q1 Financial Results
• Negative Sentiment: Multiple law firms have filed or are soliciting lead-plaintiff participation in securities class actions alleging misstatements and omissions covering May 1, 2025–Feb 27, 2026; these suits raise the risk of litigation expense, distraction and potential damages. Faruqi & Faruqi Deadline Alert
• Negative Sentiment: Allegations tied to a Hunterbrook report claim Hercules concealed software-debt concentration and misstated marks/PIK loans; firms quantify investor damages in some filings — these accusations could pressure valuations if validated. Levi & Korsinsky Investor Alert
• Negative Sentiment: An analyst at Citizens cut HTGC’s price target (though reaffirmed Outperform), signaling some sell-side caution despite the beat. Citizens Lowers Target

Hercules Capital Company Profile

Hercules Capital, Inc is a specialty finance company organized as a business development company (BDC) that provides tailored debt financing solutions to high‐growth companies. Through its external management structure, Hercules Capital extends senior secured loans, subordinated debt and growth capital designed to support research and development, expansion initiatives and working capital needs. The firm primarily partners with venture capital and private equity sponsors to finance innovative enterprises across various developmental stages.

The company's investment portfolio is concentrated in technology, life sciences and sustainable and renewable technology sectors, reflecting its focus on industries with strong growth prospects and recurring capital requirements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.